

Amendments to the Claims

Please amend claims 41, 43, 66, 72-75 and 77. Please add new claims 168-173.
Please cancel claims 42, 44-65, 67-71, 76 and 79-167 without prejudice. This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-40. (canceled)

41. (currently amended): An isolated cytotoxic T lymphocyte-inducing peptide less than 15 amino acids in length comprising the ~~the~~ [[an]] oligopeptide ~~selected from the group consisting of:~~

~~—— GIMIGVLVG (SEQ ID NO:149);~~

IMIGVLVG (SEQ ID NO:193);

~~—— IMIGVLVGVA (SEQ ID NO:194);~~

~~—— LLTFWNPPT (SEQ ID NO:224);~~

~~—— VLYGPDAPTI (SEQ ID NO:428);~~

~~—— YLWWVNGQSL (SEQ ID NO:449); and~~

~~—— YLWWVNNQSL (SEQ ID NO:450).~~

42. (canceled)

43. (currently amended): The cytotoxic T lymphocyte-inducing peptide of claim 41, wherein said peptide is IMIGVLVGV (SEQ ID NO:193).

44-65. (canceled)

66. (currently amended): The cytotoxic T lymphocyte-inducing peptide of claim 41, wherein said oligopeptide is fused to spacer or linker amino acids.

67-71. (canceled)

72. (currently amended): A composition comprising the cytotoxic T lymphocyte-inducing peptide of claim 41 and a carrier.

73. (currently amended): A composition comprising the cytotoxic T lymphocyte-inducing peptide of claim 41 and a pharmaceutically acceptable carrier.

74. (currently amended): A composition comprising the cytotoxic T lymphocyte-inducing peptide of claim 41 and a liposome.

75. (currently amended): A composition comprising the cytotoxic T lymphocyte-inducing peptide of claim 41[[,]] and one or more different peptides.

76. (canceled)

77. (currently amended): The composition of claim 75, ~~which comprises~~ further comprising a carrier.

78. (previously presented): The composition of claim 75 further comprising a pharmaceutically acceptable carrier.

79-167. (canceled)

168. (new): The composition of claim 75, wherein said one or more different peptides comprise a cytotoxic T lymphocyte epitope.

169. (new): The composition of claim 75, wherein said one or more different peptides comprise a helper T lymphocyte epitope.

170. (new): The composition of claim 169, wherein said helper T lymphocyte epitope comprises a pan-DR-binding epitope.

171. (new): The composition of claim 170, wherein said pan-DR-binding epitope comprises the peptide aKXVWANTLKAAa (SEQ ID NO:2385), wherein "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and "a" is either D-alanine or L-alanine.

172. (new): A composition comprising the cytotoxic T lymphocyte-inducing peptide of claim 41 and an antigen presenting cell.

173. (new): The composition of claim 171, wherein said antigen presenting cell is a dendritic cell.